Revelation Biosciences, Inc. (REVB): Cash & Equivalents

Annual figures by period end, from SEC filings.

$10.70M
As of 2025-12-31
$11.48M
As of 2026-06-30
+26.8%
3-year compound annual growth
n/m
5-year compound annual growth
$11.99M2020-12-31: $11.7K2021-12-31: $1.27M2022-12-31: $5.25M2023-12-31: $11.99M2024-12-31: $6.50M2025-12-31: $10.70M$10.70M
2020-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$10.70M+64.6%2026-02-26, Balance as of period end
2024-12-31$6.50M-45.8%2026-02-26, Balance as of period end
2023-12-31$11.99M+128.3%2025-03-06, Balance as of period end
2022-12-31$5.25M+312.1%2024-09-23, Balance as of period end
2021-12-31$1.27Mn/m2023-03-30, Balance as of period end
2020-12-31$11.7Kn/a2022-04-15, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Revelation Biosciences, Inc. (REVB)2025-12-31$10.70M+64.6%
Curanex Pharmaceuticals Inc (CURX)2025-12-31$5.00Mn/a
NewcelX Ltd. (NCEL)2025-12-31$2.20M+238.6%
PRF Technologies Ltd. (PRFX)2025-12-31$3.12M-26.7%
MetaVia Inc. (MTVA)2025-12-31$10.28M-35.8%
Mira Pharmaceuticals, Inc. (MIRA)2025-12-31$6.35M+124.0%
Decoy Therapeutics Inc. (DCOY)2025-12-31$10.71M+339.9%
Anebulo Pharmaceuticals, Inc. (ANEB)2025-06-30$11.63M+275.8%
Lantern Pharma Inc. (LTRN)2025-12-31$4.42M-41.1%

Compare REVB, CURX, NCEL, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗